Skip to main content

Cytrx Value Stock - Dividend - Research Selection

Cytrx

ISIN: US2328286081, WKN: A2H6Z0

Market price date: 04.06.2021
Market price: 1,39 USD




Cytrx Fundamental data and company key figures of the share

Annual reports in USD
Key figures 26-03-2021
Cash flow
Net operating cash flow -6.140.130
Capital Expenditures -25.902
Free cash flow -6.166.032
Balance sheet
Total Equity 8.870.960
Liabilities & Shareholders equity 12.060.200
Income statement
Net income -6.700.610
Eps (diluted) -0,190
Diluted shares outstanding 35.266.400
Net sales/revenue 100

Fundamental ratios calculated on: 04-06-2021

Ratios
Key figures 04-06-2021
Cash flow
P/C -8,50
   
P/FC -7,95
Balance sheet
ROI-55,56
ROE73,56
Income statement
P/E-7,32
Div. Yield0,00%
P/B5,88
P/S490.202,96


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolCYTR
Market Capitalization52.194.272,00 USD
Country
IndicesNO INDEX
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2017-11-01,1.0000/6.0000; 2012-05-16,1.0000/7.0000; 2008-03-07,10000.0000/8616.0000; 1996-02-06,1.0000/4.0000
Internetwww.cytrx.com


Description of the company

CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company´s oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company´s tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.cytrx.com